Literature DB >> 20950630

A statistical model for red blood cell survival.

Julia Korell1, Carolyn V Coulter, Stephen B Duffull.   

Abstract

A statistical model for the survival time of red blood cells (RBCs) with a continuous distribution of cell lifespans is presented. The underlying distribution of RBC lifespans is derived from a probability density function with a bathtub-shaped hazard curve, and accounts for death of RBCs due to senescence (age-dependent increasing hazard rate) and random destruction (constant hazard), as well as for death due to initial or delayed failures and neocytolysis (equivalent to early red cell mortality). The model yields survival times similar to those of previously published studies of RBC survival and is easily amenable to inclusion of drug effects and haemolytic disorders.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20950630     DOI: 10.1016/j.jtbi.2010.10.010

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  6 in total

1.  Modeling red blood cell survival data.

Authors:  Julia Korell; Frederiek E Vos; Carolyn V Coulter; John B Schollum; Robert J Walker; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-14       Impact factor: 2.745

2.  A semi-mechanistic red blood cell survival model provides some insight into red blood cell destruction mechanisms.

Authors:  Julia Korell; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-18       Impact factor: 2.745

3.  Solution and implementation of distributed lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-01       Impact factor: 2.745

4.  Modeling of red blood cell life-spans in hematologically normal populations.

Authors:  Rocío Lledó-García; Robert M Kalicki; Dominik E Uehlinger; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-31       Impact factor: 2.745

5.  Models for the red blood cell lifespan.

Authors:  Rajiv P Shrestha; Joseph Horowitz; Christopher V Hollot; Michael J Germain; John A Widness; Donald M Mock; Peter Veng-Pedersen; Yossi Chait
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-04-02       Impact factor: 2.745

6.  At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.

Authors:  Courtney D Fitzhugh; Stefan Cordes; Tiffani Taylor; Wynona Coles; Katherine Roskom; Mary Link; Matthew M Hsieh; John F Tisdale
Journal:  Blood       Date:  2017-09-08       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.